New inhaled therapy could ease lung scarring without pills
NCT ID NCT07194382
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tests an inhaled version of the drug nintedanib (AP02) in 160 adults with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants inhale the drug or a placebo twice daily for 12 weeks. The goal is to see if AP02 improves lung function and is safer than the current pill form.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CIC Mauricie
ACTIVE_NOT_RECRUITINGTrois-Rivières, Quebec, G8T 7A1, Canada
-
Dynamic Drug Advancement
RECRUITINGAjax, Ontario, L1S2J5, Canada
-
Nepean Lung and Sleep
RECRUITINGKingswood, New South Wales, 2747, Australia
Conditions
Explore the condition pages connected to this study.